Hillgene Was Awarded the Most Promising and Innovative CXO Company of the Top Value Innovative Companies in the Biomedical Science and Technology Industry of China in 2022

On November 10, the 24th Shanghai International Biotechnology and Pharmaceutical Symposium (BIO-FORUM) Series | China Biotechnology and Pharmaceutical Innovation Forum and the 2022 China Biomedical Science and Technology Innovation Value List Awards were grandly held in Shanghai. The conference focused on the theme of "Breakthrough Integration: Technological Innovation Drives High-Quality Development of the Biopharmaceutical Industry", discussed cutting-edge technologies in the biotechnology and pharmaceutical industries, investment hotspots, and insights into the future development of the industry. Spectrum Biopharma has entered the top 10 most growth-oriented innovative CXO companies.

Under the guidance of Shanghai Biomedical Science and Technology Development Center, Shanghai Jing'an District Science and Technology Committee and other units, the "2022 China Biomedical Science and Technology Innovation Value List" was initiated by Shanghai Biomedical Industry Association and Yiyun Technology. Huayi Research Institute and Yihan Think Tank provided data support for the Science and Technology Innovation Value List. Based on the growth judgment standards accumulated by Huayi Research Institute over the years, combined with basic processes such as questionnaire surveys, interviews, data aggregation and data verification, the review team standardized and comprehensively evaluated the full-year data and public information of biopharmaceutical companies in 2021, so as to select a group of companies with industry innovation value in that year and form an industry third-party objective evaluation list.

Innovative CXO List

Mainly focuses on preclinical CRO, clinical CRO, CDMO, CMO and related fields.

CXO leading companies, relying on their own first-mover advantage, gradually completed the platform integration layout. In the context of twists and turns in the innovation of the biopharmaceutical industry, they still maintained rapid growth and became the core group of the most influential CXO list. CXO rising stars may grow rapidly as top students in vertical tracks or as CDMO followers.

This time, Spectrum Biopharma won the 2022 China Biopharmaceutical Technology Innovation Value List - the most growth-oriented innovative CXO enterprise, which represents the recognition of the industry's leading units for Spectrum Biopharma's growth potential and innovation strength. Spectrum Biopharma is deeply engaged in the cell therapy CDMO business, and its CQDMO service system with "quality" as the core is committed to meeting customers' testing needs at different stages, providing professional testing and quality control services, and is committed to providing customers with complete cell therapy full-process solutions.